Photo of Benjamin L. Schlechter,  MD

Benjamin L. Schlechter, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (857) 215-0430


benjamin_schlechter@dfci.harvard.edu

Benjamin L. Schlechter, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending Physician, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am an academic medical oncologist specializing in gastrointestinal (GI) malignancies to focus on the treatment of patients with GI malignancies, with a particular focus on anal cancer, colorectal cancer, and GI neuroendocrine cancers as well as general GI oncology. I previously worked in the laboratory of Dr. Carol L. Rosenberg at Boston University School of Medicine and Dr. Donald E. Ingber at the Wyss Institute. I joined the faculty of Beth Israel Deaconess Medical Center (BIDMC) in 2014 and served as a GI oncologist as well as the Director of Inpatient Hematology and Oncology during my tenure at BIDMC. At BIDMC, I was an active participant in investigator-initiated, cooperative group, and industry funded clinical trials in GI malignancies, as well as trials involving the management of thrombosis in cancer. In my role at BIDMC, I served as a weekly discussant in the Gastrointestinal Malignancies Tumor Board and Pancreaticobiliary Malignancies Tumor Board. I saw patients in the Rectal Cancer Multidisciplinary Clinic and the Pancreatic Cancer Multidisciplinary Clinic as well as my general GI oncology clinic. I also mentored numerous fellows and residents in oncology. My current clinical activities at DFCI include five half-day sessions in the GI oncology and four weeks per year of inpatient attending service in oncology at BWH. I am refocusing my efforts on clinical investigation, using my experience as a practicing oncologist to help develop innovative clinical trials in GI malignancies. My background in clinical practice, clinical trials, medical education, and laboratory work will serve as a solid foundation for this transition.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Ore AS, Dombek GE, Cordova-Cassia CA, Quinn JF, Cataldo TE, Schlechter BL, Abrams MJ, Messaris E. Omission of or Poor Response to Preoperative Chemoradiotherapy Impacts Radial Margin Positivity Rates in Locally Advanced Rectal Cancer. Dis Colon Rectum 2021; 64:669-676. PubMed
  • Besaw RJ, Terra AR, Malvar GL, Chapman TR, Hertan LM, Schlechter BL. Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells. J Natl Compr Canc Netw 2021; 19:247-252. PubMed
  • Zwicker JI, Roopkumar J, Puligandla M, Schlechter BL, Sharda AV, Peereboom D, Joyce R, Bockorny B, Neuberg D, Bauer KA, Khorana AA. Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv 2020; 4:2254-2260. PubMed
  • Schawkat K, Tabah N, Tridente D, Schlechter BL, Singer T, Decicco C, Moser AJ, Mortele KJ. Incidental pulmonary embolism in pancreatic ductal adenocarcinoma: Impact of tumor and AJCC stages at initial staging CT. Pancreatology 2019; 19:979-984. PubMed
  • Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R, . Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight 2019. PubMed
  • Reynolds EE, Buss MK, Schlechter BL. Would You Refer This Patient With Cancer to a Palliative Care Specialist? Ann Intern Med 2019; 171:448. PubMed
  • Reynolds EE, Buss MK, Schlechter BL, Tess A. Would You Refer This Patient With Cancer to a Palliative Care Specialist?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 2019; 170:488-496. PubMed
  • Jain A, van der Meer AD, Papa AL, Barrile R, Lai A, Schlechter BL, Otieno MA, Louden CS, Hamilton GA, Michelson AD, Frelinger AL, Ingber DE. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. 2016; 18:73. PubMed
  • Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C, Pistey R, de Las Morenas A, Rosenberg CL. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 2008; 8:68. PubMed
  • Larson PS, Schlechter BL, de las Morenas A, Garber JE, Cupples LA, Rosenberg CL. Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol 2005; 23:8613-9. PubMed
  • Schlechter BL, Yang Q, Larson PS, Golubeva A, Blanchard RA, de las Morenas A, Rosenberg CL. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol 2004; 22:1830-8. PubMed
  • Wang Q, Larson PS, Schlechter BL, Zahid N, Finnemore E, de las Morenas A, Blanchard RA, Rosenberg CL. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer. Int. J. Cancer 2003; 106:923-9. PubMed
Hide